Literature DB >> 24773184

Efficient bioactive delivery of aerosolized drugs to human pulmonary epithelial cells cultured in air-liquid interface conditions.

Anke-Gabriele Lenz1, Tobias Stoeger, Daniele Cei, Martina Schmidmeir, Nora Semren, Gerald Burgstaller, Bernd Lentner, Oliver Eickelberg, Silke Meiners, Otmar Schmid.   

Abstract

In inhalation therapy, drugs are deposited as aerosols onto the air-facing lung epithelium. The currently used in vitro cell assays for drug testing, however, typically dissolve drugs in the medium, completely covering the cells, which represents an unphysiological drug application scenario. Although physiologically realistic in vitro cell culture models of the pulmonary air-blood barrier are available, reliable, easy-to-handle, and efficient technologies for direct aerosol-to-cell delivery are lacking. Here, we introduce the Air-Liquid Interface (ALI) Cell Exposure-Cloud (ALICE-CLOUD) technology, which uses principles of cloud motion for fast and quantitative delivery of aerosolized liquid drugs to pulmonary cells cultured under realistic ALI conditions. Aerosol-to-cell delivery proved to be highly efficient, reproducible, and rapid when using aerosolized fluorescein as surrogate drug. As a proof-of-concept study for the ALICE-CLOUD, we performed functional efficacy studies with the U.S. Food and Drug Administration-approved proteasome inhibitor, Bortezomib, a novel candidate drug for inhalation therapy. Aerosolized Bortezomib had a pronounced anti-inflammatory effect on human epithelial lung cells (A549), as indicated by a significant reduction of (TNFα-induced) IL-8 promoter activation. Importantly, cell-based therapeutic efficacy of aerosolized Bortezomib under ALI conditions was similar to that under dissolved and nonaerosolized submerged conditions, but with faster uptake kinetics. Our data indicate that the ALICE-CLOUD is a reliable tool for aerosolized drug screening with cells cultured under ALI conditions, which combines ease of handling with rapid, efficient, and dosimetrically accurate drug-to-cell delivery. This may pave the way for screening of inhalable drugs under physiologically more relevant and, hence, potentially more predictive conditions than the currently used submerged cell culture systems.

Entities:  

Keywords:  aerosolized drug delivery; comparison of air–liquid interface and submerged cell culture; inflammation; lung epithelial cell; proteasome inhibitor

Mesh:

Substances:

Year:  2014        PMID: 24773184     DOI: 10.1165/rcmb.2013-0479OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  27 in total

1.  Electronic Cigarette Vapor with Nicotine Causes Airway Mucociliary Dysfunction Preferentially via TRPA1 Receptors.

Authors:  Samuel Chung; Nathalie Baumlin; John S Dennis; Robert Moore; Sebastian F Salathe; Phillip L Whitney; Juan Sabater; William M Abraham; Michael D Kim; Matthias Salathe
Journal:  Am J Respir Crit Care Med       Date:  2019-11-01       Impact factor: 21.405

2.  Organotypic Models of Lung Cancer.

Authors:  Anna Pomerenke
Journal:  Curr Top Microbiol Immunol       Date:  2021       Impact factor: 4.291

Review 3.  Cells and Culture Systems Used to Model the Small Airway Epithelium.

Authors:  Rudra Bhowmick; Heather Gappa-Fahlenkamp
Journal:  Lung       Date:  2016-04-12       Impact factor: 2.584

Review 4.  Innovative preclinical models for pulmonary drug delivery research.

Authors:  Stephan Ehrmann; Otmar Schmid; Chantal Darquenne; Barbara Rothen-Rutishauser; Josue Sznitman; Lin Yang; Hana Barosova; Laurent Vecellio; Jolyon Mitchell; Nathalie Heuze-Vourc'h
Journal:  Expert Opin Drug Deliv       Date:  2020-02-23       Impact factor: 6.648

5.  Air-liquid interface cultures of the healthy and diseased human respiratory tract: promises, challenges and future directions.

Authors:  Domizia Baldassi; Bettina Gabold; Olivia Merkel
Journal:  Adv Nanobiomed Res       Date:  2021-05-06

6.  Human barrier models for the in vitro assessment of drug delivery.

Authors:  Matthias Schweinlin; Angela Rossi; Nina Lodes; Christian Lotz; Stephan Hackenberg; Maria Steinke; Heike Walles; Florian Groeber
Journal:  Drug Deliv Transl Res       Date:  2017-04       Impact factor: 4.617

Review 7.  Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung.

Authors:  Chantal Darquenne; John S Fleming; Ira Katz; Andrew R Martin; Jeffry Schroeter; Omar S Usmani; Jose Venegas; Otmar Schmid
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-02-01       Impact factor: 2.849

Review 8.  Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics.

Authors:  Arbel Artzy-Schnirman; Sivan Arber Raviv; Ofri Doppelt Flikshtain; Jeny Shklover; Netanel Korin; Adi Gross; Boaz Mizrahi; Avi Schroeder; Josué Sznitman
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 15.470

9.  Permeation of Therapeutic Drugs in Different Formulations across the Airway Epithelium In Vitro.

Authors:  Claudia Meindl; Sandra Stranzinger; Neira Dzidic; Sharareh Salar-Behzadi; Stefan Mohr; Andreas Zimmer; Eleonore Fröhlich
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

10.  The oxidative potential of differently charged silver and gold nanoparticles on three human lung epithelial cell types.

Authors:  Paul Schlinkert; Eudald Casals; Matthew Boyles; Ulrike Tischler; Eva Hornig; Ngoc Tran; Jiayuan Zhao; Martin Himly; Michael Riediker; Gertie Janneke Oostingh; Victor Puntes; Albert Duschl
Journal:  J Nanobiotechnology       Date:  2015-01-16       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.